Organic phosphoric acids and derivatives
![eMolecules 1271439-08-7 | (4,8-Bis((2-butyloctyl)oxy)benzo[1,2-b:4,5-b']dithiophene-2,6-diyl)bis(trimethylstannane) | ChemScene884.540 | C40H70O2S2Sn2 | 95.000 | CCCCCCC(CCCC)COc1c2cc(sc2c(OCC(CCCC)CCCCCC)c2cc(sc12)[Sn](C)(C)C)[Sn](C)(C)C | 100mg | 601110385](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502461756.JPG-250.jpg)
eMolecules 1271439-08-7 | (4,8-Bis((2-butyloctyl)oxy)benzo[1,2-b:4,5-b']dithiophene-2,6-diyl)bis(trimethylstannane) | ChemScene884.540 | C40H70O2S2Sn2 | 95.000 | CCCCCCC(CCCC)COc1c2cc(sc2c(OCC(CCCC)CCCCCC)c2cc(sc12)[Sn](C)(C)C)[Sn](C)(C)C | 100mg | 601110385
(4,8-Bis((2-butyloctyl)oxy)benzo[1,2-b:4,5-b']dithiophene-2,6-diyl)bis(trimethylstannane) | ChemScene | 1271439-08-7884.540 | C40H70O2S2Sn2 | 95.000 | CCCCCCC(CCCC)COc1c2cc(sc2c(OCC(CCCC)CCCCCC)c2cc(sc12)[Sn](C)(C)C)[Sn](C)(C)C | 100mg | 601110385
![eMolecules 16968-19-7 | 1,2-Bis(2-nitrophenyl)ethane | Ambeed | MFCD00024296 | 272.260 | C14H12N2O4 | 97.000 | [O-][N+](=O)c1ccccc1CCc1ccccc1[N+]([O-])=O | 10g | 490489831](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502425576.PNG-250.jpg)
eMolecules 16968-19-7 | 1,2-Bis(2-nitrophenyl)ethane | Ambeed | MFCD00024296 | 272.260 | C14H12N2O4 | 97.000 | [O-][N+](=O)c1ccccc1CCc1ccccc1[N+]([O-])=O | 10g | 490489831
1,2-Bis(2-nitrophenyl)ethane | Ambeed | 16968-19-7 | MFCD00024296 | 272.260 | C14H12N2O4 | 97.000 | [O-][N+](=O)c1ccccc1CCc1ccccc1[N+]([O-])=O | 10g | 490489831
Cayman Chemical 4-Aminophenyl Phosphate sodi
A substrate for alkaline phosphatase that can be used in enzymatic reactions to quantify ALP activity
Apexbio Technology LLC Rilmenidine Phosphate 85409-38-7 100mg
Rilmenidine phosphate (CAS 85409-38-7) is a water-soluble derivative of rilmenidine that selectively targets imidazoline I1 receptors non-adrenergic high-affinity binding sites implicated in blood pressure regulation Activation of I1 receptors modulates sympathetic outflow resulting in antihypertensive effects observed in both preclinical models and clinical studies In Hep G2 cells rilmenidine attenuates stearic acid-induced lipid accumulation associated with p38 MAPK activation and increased FXR expression In high-fat diet-fed mice rilmenidine ameliorates hepatic steatosis through imidazoline I1 receptor-mediated pathways This compound is of interest for investigating cardiovascular and metabolic disease mechanisms
Sigma Aldrich Fine Chemicals Biosciences Dihexadecyl phosphate | 2197-63-9 | MFCD00008999 | 5G
Dihexadecyl phosphate | Mol Wt: 546.85 | 2197-63-9 | MFCD00008999 | 5G
Medchemexpress LLC Dibutyl phenyl phosphate | 2528-36-1 | MFCD00438060 | 286.30 g·mol⁻¹ | C14H23O4P | 50 MG
Dibutyl phenyl phosphate is an organophosphate research reagent used primarily as a flame retardant and reported to inhibit butyrylcholinesterase (BChE). It is supplied for laboratory research use only; consult product documentation for handling, purity, and storage requirements.
- Used as a flame retardant in material testing and formulation studies.
- Inhibits butyrylcholinesterase (BChE); IC50 83.6 μM, Ki 94.5 μM.
- Documented molecular formula C14H23O4P and molecular weight 286.30 g·mol⁻¹.
- Supplied in small pack sizes appropriate for research applications.
- Certificate of analysis and supporting documentation available on request for purity and storage details.
Apexbio Technology LLC NVP-BGJ398 phosphate 1310746-10-1 200mg
NVP-BGJ398 phosphate (CAS 1310746-10-1) is a potent selective inhibitor of fibroblast growth factor receptors (FGFRs) 1 2 and 3 exhibiting low nanomolar inhibitory activity (IC50 0 9 nM for FGFR1 1 nM for FGFR3 and 1 4 nM for FGFR2) It demonstrates markedly reduced potency against FGFR4 In cellular assays NVP-BGJ398 suppresses autophosphorylation of FGFRs leading to inhibition of downstream signaling pathways such as ERK1/2 The compound effectively reduces proliferation in cancer cell lines harboring FGFR genetic alterations and promotes cell-cycle arrest and apoptosis in cells with FGFR2 mutations NVP-BGJ398 is under investigation in oncology research including phase I clinical trials